相关实验视频

Updated: Jun 26, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

聚纳米粒子修饰益生菌用于微环境重塑和针对性治疗炎症性肠病的微生物

Qinglian Hu¹, Jingyu Li¹, Tong Wang¹

¹College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310032, China.

|May 9, 2024

概括

这项研究开发了一种用于炎症性肠道疾病 (IBD) 的新型多纳米颗粒益生菌. 修改后的益生菌通过减少炎症并改善小鼠的肠道健康,有效治疗结肠炎.

科学领域:

生物材料科学生物材料科学
微生物学微生物学
胃肠病学胃肠病学

背景情况:

炎症性肠道疾病 (IBD) 涉及肠道微环境和微生物群的复杂破坏.
聚醇具有广泛的生物活性和兼容性,使其成为IBD治疗平台的前景.
制定重塑IBD微环境和调节肠道微生物群的策略至关重要.

研究的目的:

创建一个使用纳米结构聚和益生菌用于IBD治疗的协作平台.
在IBD小鼠模型中研究改性益生菌的治疗潜力.
评估工程益生菌系统的同时药物输送能力.

主要方法:

使用酸 (TA) 和自聚合芳香二醇 (BDT) 制造纳米结构的pBDT-TA.
在 *Escherichia coli* Nissle 1917 上层层地涂上 pBDT-TA 和藻酸盐 (SA),形成 EcN@SA-pBDT-TA.
改性益生菌对氧化和炎症应激的耐药性的评估.
评估EcN@SA-pBDT-TA在硫酸 (DSS) 诱导的大肠炎小鼠中的疗效,包括结肠积累,保留,炎症控制,屏障修复和微生物群调节.

主要成果:

纳米结构的pBDT-TA在体外显示出显著的抗氧化和抗炎性质.
修改后的益生菌 (EcN@SA-pBDT-TA) 在IBD小鼠的结肠中增强了存活率和积累.
通过控制炎症,修复肠道屏障和调节肠道微生物群,EcN@SA-pBDT-TA有效地缓解了DSS诱导的大肠炎.
使用EcN@SA-pBDT-TA同时提供药物,在IBD模型中改善了治疗结果.

结论:

纳米结构的多改性益生菌为IBD治疗提供了一个可行的协作平台.
这种方法增强了肠道中的益生菌弹性和治疗疗效.
工程化益生菌显示出重塑IBD微环境和恢复微生物群平衡的潜力.

关键词:

药物输送是药物输送的过程.炎症性肠道疾病炎症性肠道疾病微环境的改造微环境的改造纳米结构的多醇.益生菌是一种益生菌.

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...